Citation: | LIU Chu-chu, HUANG Jie, LIU Yu-hui, ZHOU Hua-dong, XU Li. Risk factors and recurrence characteristics of neuromyelitis optica spectrum disease[J]. Chinese Journal of General Practice, 2021, 19(5): 715-718,829. doi: 10.16766/j.cnki.issn.1674-4152.001899 |
[1] |
CHEN H, LIU S M, ZHANG X X, et al. Clinical features of patients with multiple sclerosis and neuromyelitis optica spectrum disorders[J]. Chin Med J (Engl), 2016, 129(17): 2079-2084. doi: 10.4103/0366-6999.189046
|
[2] |
WINGERCHUK D M, BANWELL B, BENNETT J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. doi: 10.1212/WNL.0000000000001729
|
[3] |
HOUZEN H, KONDO K, NⅡNO M, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan[J]. Neurology, 2017, 89(19): 1995-2001. doi: 10.1212/WNL.0000000000004611
|
[4] |
JIAO Y, FRYER J P, LENNON V A, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica[J]. Neurology, 2013, 81(14): 1197-1204. doi: 10.1212/WNL.0b013e3182a6cb5c
|
[5] |
VISWANATHAN S, WAH L M. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia[J]. Mult Scler, 2019, 25(11): 1452-1461. doi: 10.1177/1352458518792430
|
[6] |
SUN H, SUN X, LI J, et al. Gender differences among Chinese patients with neuromyelitis optica spectrum disorders[J]. Mult Scler Relat Disord, 2017, 17: 5-8. doi: 10.1016/j.msard.2017.06.008
|
[7] |
PALACE J, LIN D Y, ZENG D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders[J]. Brain, 2019, 142(5): 1310-1323. doi: 10.1093/brain/awz054
|
[8] |
KUNCHOK A, MALPAS C, NYTROVA P, et al. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2020, 38: 101868. doi: 10.1016/j.msard.2019.101868
|
[9] |
AKAISHI T, TAKAHASHI T, FUJIHARA K, et al. Risk factors of attacks in neuromyelitis optica spectrum disorders[J]. J Neuroimmunol, 2020, 343: 577236. doi: 10.1016/j.jneuroim.2020.577236
|
[10] |
HOR J Y, ASGARI N, NAKASHIMA I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide[J]. Front Neurol, 2020, 11: 501. doi: 10.3389/fneur.2020.00501
|
[11] |
WINGERCHUK D M, HOGANCAMP W F, O'BRIEN P C, et al. The clinical course of neuromyelitis optica (Devic's syndrome)[J]. Neurology, 1999, 53(5): 1107. doi: 10.1212/WNL.53.5.1107
|
[12] |
MEALY M A, MOSSBURG S E, KIM S H, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions[J]. Mult Scler Relat Disord, 2019, 28: 64-68. doi: 10.1016/j.msard.2018.12.011
|
[13] |
RAFIEE F, TARJOMAN T, MOGHADASI A N, et al. Stressful life events, socioeconomic status, and the risk of neuromyelitis optica spectrum disorder: A population-based case-control study[J]. Mult Scler Relat Disord, 2020, 46: 102544. doi: 10.1016/j.msard.2020.102544
|
[14] |
ABDOLLAHPOUR I, NEDJAT S, SAHRAIAN M A, et al. Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study[J]. Mult Scler, 2017, 23(10): 1328-1335. doi: 10.1177/1352458516677867
|
[15] |
ETEMADI A, KHADEMI H, KAMANGAR F, et al. Hazards of cigarettes, smokeless tobacco and waterpipe in a Middle Eastern Population: a Cohort Study of 50000 individuals from Iran[J]. Tob Control, 2017, 26(6): 674-682. doi: 10.1136/tobaccocontrol-2016-053245
|
[16] |
KLAWITER E C, BOVE R, ELSONE L, et al. High risk of postpartum relapses in neuromyelitis optica spectrum disorder[J]. Neurology, 2017, 89(22): 2238-2244. doi: 10.1212/WNL.0000000000004681
|
[17] |
TONG Y, LIU J, YANG T, et al. Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis[J]. Mult Scler Relat Disord, 2018, 25: 61-65. doi: 10.1016/j.msard.2018.07.006
|
[18] |
FRAGOSO Y D, SOUSA N A C, ALVES-LEON S V, et al. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2019, 27: 392-396. doi: 10.1016/j.msard.2018.11.031
|
[19] |
CHANG V T W, CHANG H M. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder[J]. Neuropathol Appl Neurobiol, 2020, 46(3): 199-218. doi: 10.1111/nan.12574
|
[20] |
ZHANG W, CUI L, ZHANG Y, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population[J]. J Neurol, 2020, 267(4): 1197-1205. doi: 10.1007/s00415-019-09685-3
|
[21] |
JARIUS S, RUPRECHT K, WILDEMANN B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients[J]. J Neuroinflammation, 2012, 9(1): 14. doi: 10.1186/1742-2094-9-14
|
[22] |
陈彧, 赵建民, 王夏红, 等. 视神经脊髓炎的视觉诱发电位和MRI对照研究[J]. 眼科新进展, 2008, 28(9): 698-699. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ200809030.htm
|
[23] |
MA X, KERMODE A G, HU X, et al. Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy[J]. Mult Scler Relat Disord, 2020, 46: 102522. doi: 10.1016/j.msard.2020.102522
|